HC Wainwright Has Positive View of Celcuity FY2026 Earnings

Key Points

• HC Wainwright has raised its FY2026 earnings per share estimate for Celcuity to ($3.88), improving from a previous estimate of ($4.11), while maintaining a "Buy" rating with a price target of $50.00.
• Celcuity's stock has shown significant interest from institutional investors, with 63.33% of the stock currently held by such entities and considerable stake increases reported by multiple funds.
• The stock has experienced notable trading activity, with a recent sale by Director David Dalvey of 100,000 shares for approximately $4.4 million, resulting in a significant decrease in his ownership.

Celcuity, Inc. (NASDAQ:CELC - Free Report) - Stock analysts at HC Wainwright upped their FY2026 earnings per share estimates for Celcuity in a research note issued on Monday, July 28th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($3.88) per share for the year, up from their prior estimate of ($4.11). HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Celcuity's current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity's FY2027 earnings at $0.81 EPS, FY2028 earnings at $4.05 EPS and FY2029 earnings at $7.13 EPS.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.09.

Several other research firms have also recently issued reports on CELC. Leerink Partners upped their price target on Celcuity from $28.00 to $60.00 and gave the company an "outperform" rating in a report on Monday. Needham & Company LLC restated a "buy" rating and set a $29.00 price target on shares of Celcuity in a report on Monday. Finally, Stifel Nicolaus began coverage on shares of Celcuity in a research report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Celcuity currently has an average rating of "Buy" and an average price target of $39.20.

Celcuity Stock Performance

Shares of NASDAQ CELC traded up $0.74 during midday trading on Thursday, hitting $39.91. 1,549,488 shares of the company's stock were exchanged, compared to its average volume of 2,299,647. The firm has a market cap of $1.55 billion, a P/E ratio of -13.17 and a beta of 0.67. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.61 and a quick ratio of 6.61. Celcuity has a twelve month low of $7.57 and a twelve month high of $46.42. The stock's 50 day moving average price is $15.25 and its 200-day moving average price is $12.28.

Insider Buying and Selling

In other news, Director David Dalvey sold 100,000 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the completion of the transaction, the director owned 125,000 shares of the company's stock, valued at $5,497,500. The trade was a 44.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 15.77% of the company's stock.

Institutional Investors Weigh In On Celcuity

Several institutional investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP lifted its position in Celcuity by 59.0% during the 1st quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company's stock worth $43,046,000 after buying an additional 1,579,182 shares in the last quarter. Soleus Capital Management L.P. lifted its holdings in shares of Celcuity by 106.0% during the 4th quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company's stock worth $33,577,000 after acquiring an additional 1,319,700 shares during the period. Janus Henderson Group PLC bought a new position in Celcuity in the 4th quarter valued at approximately $8,468,000. Ameriprise Financial Inc. lifted its stake in Celcuity by 45.9% in the 4th quarter. Ameriprise Financial Inc. now owns 447,171 shares of the company's stock valued at $5,853,000 after purchasing an additional 140,642 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Celcuity in the 1st quarter valued at approximately $704,000. 63.33% of the stock is owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.